 HOUSTON, Oct. 18, 2021 PRNewswire -- Moleculin Biotech, Inc. , Nasdaq: MBRX Moleculin or the Company, a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported interim results from its U.S. Phase 1b2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma STS lung metastases, which documented preliminary clinical activity for Annamycin. The Phase 1b2 study is a U.S. multi-center, open-label, single-arm study that in Phase 1b will determine the maximum tolerated dose MTD or the recommended Phase 2 dose RP2D and safety of Annamycin. 